London Lucien P J Ooi
Overview
Explore the profile of London Lucien P J Ooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoang M, Koh Y, Sultana R, Allen J, Moris D, Cheow P, et al.
Int J Surg
. 2024 Sep;
110(11):7058-7066.
PMID: 39248314
Background: Surgical resection is a curative therapy for early-stage hepatocellular carcinoma (HCC) patients meeting the Milan criteria as well as a widely used therapy in intermediate-stage HCC. However, intermediate-stage HCC...
2.
Wee I, Moe F, Sultana R, Ang R, Quek P, Goh B, et al.
J Hepatocell Carcinoma
. 2022 Aug;
9:839-851.
PMID: 35999856
Objective: We aimed to prognosticate survival after surgical resection of HCC stratified by stage with amalgamation of the modified Barcelona Clinic Liver Cancer (BCLC) staging system and location of tumour....
3.
Jin Y, Wong Y, Goh B, Chan C, Cheow P, Chow P, et al.
Sci Rep
. 2019 Jul;
9(1):10464.
PMID: 31320713
Hepatocellular carcinoma (HCC) is the fifth most common cancer with high mortality, due to late diagnosis and limited treatment options. Blood miRNAs, which circulate in a highly stable, cell-free form,...
4.
Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam V, et al.
J Hepatol
. 2015 May;
63(4):863-73.
PMID: 25980764
Background & Aims: Patients with advanced hepatocellular carcinoma (HCC) continue to have a dismal prognosis. Early recurrence, metastases and angiogenesis are the major obstacles to improve the outcome of HCC....
5.
Xia H, Chen J, Shi M, Deivasigamani A, Ooi L, Hui K
Oncotarget
. 2015 Feb;
6(8):5990-6000.
PMID: 25714025
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. The inability of chemotherapeutic drugs to selectively target HCC tumor cells because of their predominant resistant phenotype to...
6.
Xia H, Ooi L, Hui K
Hepatology
. 2013 Mar;
58(2):629-41.
PMID: 23471579
Unlabelled: Tumor recurrence and metastases are the major obstacles to improving the prognosis of patients with hepatocellular carcinoma (HCC). To identify novel risk factors associated with HCC recurrence and metastases,...
7.
Xia H, Ooi L, Hui K
PLoS One
. 2012 Sep;
7(9):e44206.
PMID: 22962603
The down-regulation of miR-214 has previously been observed in human hepatocellular carcinoma (HCC). Here, we demonstrated the down-regulation of miR-214 is associated with cell invasion, stem-like traits and early recurrence...
8.
Chew V, Chen J, Lee D, Loh E, Lee J, Lim K, et al.
Gut
. 2011 Sep;
61(3):427-38.
PMID: 21930732
Objective: Hepatocellular carcinoma (HCC) is a heterogeneous disease with poor prognosis and limited methods for predicting patient survival. The nature of the immune cells that infiltrate tumours is known to...
9.
Wang S, Ooi L, Hui K
Clin Cancer Res
. 2011 Aug;
17(18):6040-51.
PMID: 21825042
Purpose: To assess the significance of Rac GTPase-activating protein 1 (RACGAP1) expression in identifying HBV-positive human hepatocellular carcinoma (HCC) patients who are at high risk for recurrent disease. Experimental Design:...
10.
Subramaniam K, Ooi L, Hui K
Cancer Lett
. 2010 Jul;
297(2):259-68.
PMID: 20599318
Insulin-like growth factor binding protein-3 (IGFBP-3) plays key roles in regulating cell growth, differentiation, and apoptosis in a variety of cellular systems. We have observed significant down-regulation of IGFBP-3 expression...